VivoSeq
Other

Disc Degenerative Disease

2

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

Disc Degenerative Disease is an early-stage landscape with 2 programs across 3 companies. The most active players are Xiangbei Welman Pharmaceutical Co., Ltd, Boehringer Ingelheim, Cartago Biotech Pty Ltd.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

X

Xiangbei Welman Pharmaceutical Co., Ltd

1 program

PreclinicalBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

PreclinicalC

Cartago Biotech Pty Ltd

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical2

High-Dose

Xiangbei Welman Pharmaceutical Co., Ltd

Low Dose

Boehringer Ingelheim

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Not yet recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase I/II, Open-label, Single Administration Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Efficacy of Intradiscal rhGDF-6 for the Treatment of Lumbar Disc Degeneration
Not yet recruiting·CCartago Biotech Pty Ltd·Preclinical·NCT07668466·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)